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REVIEW ARTICLE

Lisocabtagene Maraleucel in Relapsed or Refractory
Diffuse Large B Cell Lymphoma: What is
the Evidence?
Mohamed A. Kharfan-Dabaja*, Farah Yassine, Muhamad Alhaj Moustafa,
Madiha Iqbal, Hemant Murthy
Division of HematologyeOncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville,
FL, USA

Abstract
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product,
with a CD3z activatory domain connected to 4-1BB costimulatory domain. Liso-cel, unlike the other two approved
productsdaxicabtagene ciloleucel and tisagenlecleuceldis manufactured separately from CD4 and CD8 T cells and then
administered as a sequential infusion of the two components at equal target doses. The approval of liso-cel was based on
the results of Transcend NHL 001, a single-arm, open-label, multicenter, seamless design trial that enrolled 344 patients,
of whom 269 received conforming liso-cel. The most common histology was diffuse large B cell lymphoma, not
otherwise speciﬁed (DLBCL NOS; n ¼ 137, 51%) followed by DLBCL transformed from indolent lymphomas (n ¼ 78,
29%). Encouraging results were reported, yielding an objective response rate across all dose levels of 73% [complete
remission (CR) ¼ 53%], with an estimated duration of response at 1 year of 55% for all patients and 65% for those
achieving a CR. The estimated 12-month overall survival was 58% for all patients and 86% for those achieving a CR.
Cytokine release syndrome and neurological adverse events were reported in 42% and 30%, respectively. This review
summarizes the evidence on the safety and effectiveness of liso-cel, resulting in its addition to the current treatment
armamentarium of relapsed or refractory large B cell lymphoma.
Keywords: CD19, Chimeric antigen receptor T cell, Diffuse large B cell non-Hodgkin lymphoma, Lisocabtagene
maraleucel

1. Introduction

C

himeric antigen receptor T cell (CAR T)
therapy represents a new addition to the
treatment of relapsed or refractory (R/R) B cell
lymphoid malignancies [1e5]. Historically, patients
with R/R diffuse large B cell lymphoma (DLBCL)
had low anticipated complete remission (CR) rates
to subsequent chemoimmunotherapy combinations,
particularly after failing two or more lines of therapy
[6]. Crump et al. [6] in the retrospective nonHodgkin lymphoma research study known as
SCHOLAR-1 showed that the probability of

attaining a CR in this population is less than 20%
and the anticipated survival is generally poor. The
role of high-dose therapy and autologous hematopoietic cell transplantation (auto-HCT) in DLBCL is
limited to those who demonstrate an objective
response rate (ORR), preferably a CR, to second-line
therapy [7,8]. Unfortunately, auto-HCT has no role
in patients with chemoresistant disease, a population that represents a therapeutic challenge.
CAR T therapy has emerged as an effective
treatment of R/R DLBCL, even after failing two or
more lines of therapy. Thus far, the United States
Food and Drug Administration (FDA) has approved
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three CAR T products for commercial use [2e4].
One of those products is lisocabtagene maraleucel
(liso-cel), which is an autologous CD19-directed
CAR T product with a CD3z activatory domain
connected to 4-1BB costimulatory domain [4].
Different from the other two approved products,
namely axicabtagene ciloleucel (axi-cel) and tisagenlecleucel, liso-cel is manufactured separately
from CD4 and CD8 T cells, and then administered
as a sequential infusion of the two components at
equal target doses. A recently published, large
multicenter, seamless design, Transcend NHL 001
study (TRANSCEND) treated 269 patients (median
age, 63 years), who were heavily pretreated, with a
median of three prior therapies and 67% having
refractory disease [4]. The ORR and CR rates were
73% and 53%, respectively [4]. Liso-cel is approved
for R/R large B cell lymphoma after two or more
lines of systemic therapy, including DLBCL not
otherwise speciﬁed (NOS), DLBCL arising from
indolent lymphoma, high-grade B-cell lymphoma,
primary mediastinal large B cell lymphoma
(PMBCL), and follicular lymphoma (FL) grade 3B.
Here, we provide a comprehensive review of lisocel in DLBCL and highlight available data of
ongoing studies in other histologies.

2. Liso-cel in large B cell lymphoma
2.1. Efﬁcacy
Transcend NHL 001 was a single-arm, open-label,
multicenter, seamless design trial that led to the
approval of liso-cel for commercial use [4]. The
included histologies comprised DLBCL, high-grade
B cell lymphoma with rearrangements of MYC and
either BCL2, BCL6, or both, DLBCL transformed from
any indolent lymphoma, PMBCL, and FL grade 3B
[4]. Patients must have received two or more prior
lines of systemic treatment and they could have
received a previous auto-HCT or allogeneic HCT [4].
Lymphodepleting chemotherapy consisting of ﬂudarabine 30 mg/m2 and cyclophosphamide 300 mg/
m2 was administered intravenously daily for 3 days
[4]. After 2e7 days from completion of lymphodepleting chemotherapy, liso-cel was administered as
two sequential infusions of CD8 and CD4 CAR T
cells, at one of three target dose levels: (a) 50  10⁶
CAR þ T cells (dose level 1), (b) 100  10⁶ CAR T cells
(dose level 2), and (c) 150  10⁶ CAR T cells (dose level
3) [4]. Although 344 patients were enrolled, only 294
received the intended CAR T cell infusion; however,
25 of those patients received a nonconforming
product. In the end, 269 patients received conforming
liso-cel and the majority were male (n ¼ 174, 65%) [4].
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The most common histology was DLBCL NOS (n ¼
137, 51%) followed by DLBCL transformed from
indolent lymphomas (n ¼ 78, 29%). A total of 139
(52%) participants had failed  3 lines of therapy [4].
The study allowed for bridging therapy to be
administered at the investigator’s discretion, as was
the case in 159 (59%) patients [4]. The authors did not
identify a maximum tolerated dose (MTD).4 The
median time to ﬁrst CR or partial response (PR) was 1
month [4]. The ORR across all dose levels was 73%
(CR ¼ 53%) [4]. The ORR for dose levels 1, 2, and 3
were 67.5%, 74%, and 73.2%, respectively [4]. The
median duration of response (DOR) was not reached
at the time results were reported. The estimated DOR
at 1 year was 55% for all patients and 65% among
those who achieved a CR [4]. The 1-year progressionfree survival (PFS) was 44% for all patients and 65%
among those who attained a CR [4]. The median
overall survival (OS) was 21.1 months [4]. The estimated 12-month OS was reported as 58% for all patients and 86% for those who achieved a CR [4]. This
certainly represents a signiﬁcant improvement in OS
compared to therapies that preceded CAR T cell
availability [4].
Pertaining to other histologies, DOR and PFS in
PMBCL and DLBCL transformed from FL were
longer than for other subtypes. Moreover, the median OS was not reached for patients with highgrade B cell lymphoma, transformed FL, FL grade
3B, or PMBCL [4].
The recommended target dose for liso-cel is 100 
10⁶ CAR T cells (50  10⁶ CD8 and 50  10⁶ CD4
CAR T cells).
2.2. Toxicities
In TRANSCEND NHL 001, 139 patients were
evaluable for dose limiting toxicities (DLTs). Only 9
(6%) had DLTs with one reported death from diffuse
alveolar hemorrhage at the lowest tested dose. As
such, no MTD or a relationship between dose levels
and toxicity was identiﬁed [4].
Two hundred and sixty-seven (99%) patients had
treatment-emergent adverse events (TEAEs) with
the most common being neutropenia (n ¼ 169, 63%)
followed by anemia (n ¼ 129, 48%), fatigue (n ¼ 119,
44%), and cytokine release syndrome (CRS) (n ¼
113, 42%) [4]. A total of 213 patients (79%) experienced grade 3 or greater TEAE with the most common being neutropenia (n ¼ 161, 60%) followed by
anemia (n ¼ 101, 37%) and thrombocytopenia (n ¼
72, 27%). Only six (2%) patients experienced grade 3
or greater CRS [4].
Speciﬁcally for CRS of all grades (graded per Lee
et al. criteria [9]), the median time to both onset and
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resolution was reported at 5 days each, with the
most common symptoms being fever (95%) followed
by hypotension (49%). No patient died because of
CRS. The authors reported that 20% of patients
received either tocilizumab alone, corticosteroids
alone, or a combination of tocilizumab and corticosteroids to treat CRS. For patients who received
tocilizumab, the median number of doses was 1
(range, 1e4) with median time from onset of CRS to
administration of tocilizumab being 1.5 (range, 0e8)
days. Only one person was treated with siltuximab
and anakinra for grade 4 CRS [4].
Neurological events (NEs) were graded by the
investigators using National Cancer Institute common terminology criteria for adverse events version
4.03. Eighty (30%) patients experienced neurological
adverse events (NAEs) of all grades [4]. Twentyseven (10%) experienced grade 3 or greater NAE;
two of these patients had evidence of secondary
central nervous system (CNS) lymphoma at enrollment. Median time to onset and resolution were 9
and 11 days, respectively, for NAE of any grade [4].
Fifty-eight (73%) patients experienced both CRS and
NAE. The most common NAE of any grade was
encephalopathy (71%) followed by tremors (33%),
aphasia (33%), and delirium (20%) [4]. The most
common grade 3 or greater NAE was encephalopathy (7%) [4]. No patient died because of NAE, and
4% were admitted to the intensive care unit (ICU)
for management of CRS, NAE, or both. A higher
incidence of CRS, NAE, or both was observed in
patients who had a high tumor burden prior to lisocel infusion [4].
For patients who received liso-cel in the outpatient setting, 18 (72%) were hospitalized because of
AEs at a median of 5 days [4]. Additional TEAE that
have been associated previously with CAR T cell
therapy such as prolonged cytopenias at Day 29,
hypogammaglobinemia, and grade 3 or higher infections were reported in 37%, 14%, and 12% patients, respectively [4]. It is important to note that
most patients had resolution of cytopenias by Day
180 post-infusion [4].

3. Comparing liso-cel to other commercially
approved CAR T cell products
3.1. Efﬁcacy
The primary end point of the TRANSCEND NHL
001 study was the ORR of patients who received the
DL 2 at the conﬁrmational study phase; ORR was
74% and CR was 54%. In the intention-to-treat set of
344 patients who underwent leukapheresis, ORR
and CR rates were 61% and 44%, respectively. The

median time to response was 1 (range, 0.7e8.9)
month, and the median PFS was 6.8 months. For
patients who achieved a CR, median PFS was not
reached. The estimated 1-year OS was 58% for the
entire population and 86% for patients who achieved a CR [4].
The other two commercially approved CD19 CAR
T cell products for treatment of R/R B cell lymphomas are axi-cel, evaluated in the ZUMA-1 [2],
and tisagenlecleucel in the JULIET trial [3]. Among
the 101 patients who received axi-cel, the ORR was
82% (CR ¼ 54%). The median time to response was
also 1 month, and the median PFS was 5.8 months.
The estimated 1-year OS was 59% [2]. Among the 93
patients who received tisagenlecleucel, ORR was
52% with CR in 40%. The median PFS has not been
reached for patients who had a CR. The estimated
OS at 1 year was 49% among all patients and 90%
for those in CR [3].
A recently published matching-adjusted indirect
comparison (MAIC) of liso-cel versus axi-cel
demonstrated a comparable MAIC-weighted efﬁcacy outcomes between these two products for ORR,
CR, OS, and PFS [10]. However, MAIC-weighted
safety outcomes favored liso-cel by showing lower
odds of all-grade and  grade 3 CRS and studyspeciﬁc NEs [10].
These three products have minor differences in
their FDA-approved indications based on histologies included in their respective studies. The ORRs
and CRs of various histologies per each product are
summarized in Table 1.
3.2. Toxicities
Safety analysis in the TRANSCEND NHL 001 trial
included 269 patients, among whom 127 (47%)
developed CRS, NAE, or both, leading to 19 (7%)
admissions to the ICU [4]. The CRS of any grade
occurred in 113 (42%) patients within a median
onset of 5 days after infusion, including six (2%)
patients reporting grade  3 CRS. The most common CRS symptoms included fever (95%) and hypotension (49%) [4]. CRS was managed with
tocilizumab (10%), corticosteroids (2%), or both (8%)
[4]. NEs of any grade were reported in 80 (30%)
patients within a median onset of 9 days, including
27 (10%) grade  3 events [4]. NAEs were mostly
manifested as encephalopathy (71%), tremor and
aphasia (33%), and delirium (20%). Notably, no patients died from either CRS or NE. Other treatmentrelated adverse events included headache (30%),
dizziness (22%), prolonged cytopenias at Day 29
(37%), hypogammaglobulinemia (14%), and grade 
3 infections (12%) [4].
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Table 1. Efﬁcacy of CAR T Products in TRANSCEND NHL 001, ZUMA-1, and JULIET studies.
CAR-T product

ref

All
histologies

R/R
DLBCLNOS

R/R
high-grade
B cell
lymphoma

R/R primary
mediastinal
large B cell
lymphoma

R/R DLBCL
arising from
follicular
lymphoma

R/R DLBCL
arising from
indolent lymphoma
(apart from follicular
lymphoma)

R/R
Follicular
lymphoma
grade 3B

Yes
25 (75.8)
20 (60.6)

Yes
11 (78.6)
7 (50)

Yes
48 (84.2)
36 (63.2)

Yes
11 (61.1)
7 (38.9)

Yesa
2 (100)
2 (100)
No
Not
included
e
No
Not
included
e

Lisocabtagene
maraleucel4

Included
ORR, n (%)
CR, n (%)

186 (73)
136 (53)

Yes
89 (67.9)
64 (48.9)

Axicabtagene
ciloleucel2

Included
ORR, n (%)

83 (82)

Yes
63 (82)b

Yes
4 (100)c

Yes
6 (75)

Yes
14 (87.5)

CR, n (%)

55 (54)

38 (49)b

3 (75)c

6 (75)

12 (75)

No
Not
included
e

Included
ORR, n (%)

48 (52)

CR, n (%)

37 (40)

Yes
Not
reportedd
e

Yes
Not
reportedd
e

No
Not
included
e

Yes
Not
reportedd
e

No
Not
included
e

Tisagenlecleucel3

Note. CAR ¼ chimeric antigen receptor; CR ¼ complete remission; DLBCL ¼ diffuse large B cell lymphoma; HGBCL ¼ high-grade B cell
lymphoma; NOS ¼ not otherwise speciﬁed; ORR ¼ objective response rate; R/R ¼ relapsed or refractory.
a
Only two patients included in analysis.
b
Included all patient with large B cell lymphoma.
c
Only four patients (double hit or triple hit HGBCL).
d
Per phase 2 JULIET study authors; the response was comparable between all histological groups included in the study.

In the ZUMA-1 study, CRS and NE occurred in
93% and 64% of patients who received axi-cel,
respectively [2]. Grade  3 CRS and grade  3 NE
were reported in 13% and 28% of patients, respectively [11]. As for the JULIET study, tisagenlecleucel
was associated with CRS and NE in 58% and 21% of
patients, respectively, including grade  3 CRS and
grade  3 NE in 22% and 12% of patients, respectively [3]. Table 2 compares toxicities associated with
each of the three available CAR T cell products.
Notwithstanding the limitations of nonrandomized comparisons, liso-cel appears to have a
lower incidence of CRS and NAE relative to axi-cel
or tisagenlecleucel. The higher rates of grade  3
CRS reported in the JULIET study could be attributed to the use of a different set of grading criteria
[12], compared to the Lee et al. [9] criteria used in
TRANSCEND NHL 001 and ZUMA-1. Notably as
well, broader eligibility criteria were followed in the
TRANSCEND NHL 001 trial, allowing for more

generalizability of the safety and efﬁcacy results,
which could be closely replicated in the real-world
setting [4].

4. Liso-cel in other B cell histologies
Various commercially available autologous CD19
CAR T products have demonstrated efﬁcacy in B cell
malignancies apart from DLBCL. KTE-X19 is
approved for mantle cell lymphoma (MCL) after
demonstrating impressive ORR and CR rates in a
highly pretreated population [5]. Also, axi-cel
received approval for R/R FL, without evidence of
transformation into DLBCL, after demonstrating
ORR and CR rates of 92% and 76%, respectively,
despite a large number of patients (64%) having failed
three or more prior lines of treatment [13]. Below, we
summarize the results of studies evaluating liso-cel in
these histologies. Some of these results may represent
interim analyses or preliminary results.

Table 2. Treatment-Related Toxicity in TRANSCEND, ZUMA-1, and JULIET Studies.
Study [ref]

CAR T-cell Treated
Safety
Any grade CRS grade Any grade NE grade Infections Cytopenia TLS
product
patients (n) -evaluable CRS n (%)  3n (%)
NE n (%)  3n (%) grade 
n (%)
n (%)
patients (n)
3n (%)

TRANSCEND Liso-cel
NHL 001 [4]
ZUMA-1 [2]
Axi-cel
JULIET [3]
Tisagen
-lecleucel

294

269

113 (42)

6 (2)

80 (30)

27 (10)

33 (12)

100 (37)

2 (1)

101
111

101
111

94 (93)
64 (58)

13 (13)
24 (22)

65 (64)
23 (21)

28 (28)
13 (12)

NA
22 (20)

NA
49 (44)

NA
1 (1)

Note. CAR ¼ chimeric antigen receptor; CRS ¼ cytokine release syndrome; NE ¼ neurological event; NA ¼ not available; TLS ¼ tumor
lysis syndrome.
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4.1. Liso-cel in MCL
MCL is a rare aggressive subtype of non-Hodgkin
lymphoma with an annual incidence of 0.8 per
100,000 population in the United States [14]. The
median survival of MCL is reported to be 3 to 5
years, although in younger patients treated with
intensiﬁed cytarabine-based induction regimens
and auto-HCT it can be as high as 10 years [15].
Prognosis for R/R refractory MCL is considerably
worse. The efﬁcacy of ibrutinib in this setting has
been remarkable with a median PFS of 13.9 months,
but in patients who progress on ibrutinib, the median OS was only 8.4 months [16]. Given the success
of CD19 CAR T therapy with KTE-X19 in R/R MCL
with progression on Bruton tyrosine kinase (BTK)
inhibitor [5], it certainly supports investigating the
efﬁcacy of liso-cel in R/R MCL.
4.1.1. Efﬁcacy and toxicity of liso-cel in MCL
As part of the TRANSCEND-NHL-001 clinical
trial (ClinicalTrials.gov Identiﬁer: NCT03484702), a
cohort of MCL with R/R disease after one or more
prior lines of therapy were included. Findings from
the phase 1 dose escalation portion were recently
presented at the American Society of Hematology
meeting in 2020 [17]. A total of 41 patients underwent leukapheresis but only 32 received liso-cel (six
at DL1 of 50  106 CAR T cells and 26 at DL2 of 100
 106 CAR T cells) [17]. MCL patients were heavily
pretreated with a median of 3 (1e7) prior systemic
therapies, and 87.5% had received a BTK inhibitor.
More than half (53%) received bridging therapy
prior to liso-cel. The resulting ORR and CR rates
were 84% and 59%, respectively [17]. Dose expansion at DL2 is currently accruing.
Toxicities were generally manageable. CRS (all
grades) was reported in 50% of patients, although
only one patient in the DL2 had CRS grade 3 or
higher. Interestingly, CRS onset was reported at a
median of 6 (2e10) days, which is later than what
was reported with KTE-X19 [5,17]. NAEs were reported in 28% of patients, with a one-third being
grade 3 [17]. These preliminary results are deﬁnitely
promising. Final results are awaited to conﬁrm these
ﬁndings.
4.2. Liso-cel in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) represents
the most prevalent leukemia in the Western Hemisphere [18]. Despite therapeutic advances with
incorporation of BTK, BCL2 inhibitors, and others,
the disease remains incurable unless patients are
offered
an
allogeneic
HCT
(allo-HCT).

Unfortunately, allo-HCT could be contraindicated
in this population because of advanced age, suboptimal performance status, and/or existing
comorbidities. Moreover, despite the availability of
better tolerated reduced intensity preparative regimens, the anticipated nonrelapse mortality still exceeds 20% [19].
4.2.1. Efﬁcacy and toxicity of liso-cel in CLL
Much of the rationale for investigating liso-cel
(JCAR017) for CLL stems from experience with its
predecessor CD19 CAR T known as JCAR014. In
fact, JCAR017 differs slightly from JCAR014.
Although both JCAR014 and JCAR017 target CD19,
have set deﬁned composition of CD4/CD8 CAR T
cells, and have the same 4-1BB costimulatory
signaling, the two products differ in that JCAR014
contains CD28 transmembrane domain whereas
JCAR017 possesses immunoglobulin 4 (IgG4)
transmembrane domain.
JCAR014 has demonstrated efﬁcacy and ability to
achieve some durable responses in patients refractory to or having relapsed after ibrutinib therapy. It was also reported that higher ORR and
deeper remissions were attained when ibrutinib was
administered concurrently with JCAR014 [20].
Given these ﬁndings, the efﬁcacy of CD19 CAR T
therapy in CLL/small lymphocytic lymphoma (SLL)
with or without a concurrent BTK inhibitor is being
investigated in the ongoing TRANSCEND-CLL 004
study (ClinicalTrials.gov Identiﬁer: NCT03331198).
Most recent ﬁndings presented from phase 1 dose
escalation trial in patients with R/R CLL were reported at the American Society of Clinical Oncology
Annual Meeting in 2019 [21]. In this study, patients
had received two or more prior lines of therapy,
including BTK inhibitors, unless medically contraindicated, and had an Eastern Cooperative
Oncology Group performance status (ECOG PS) 
1. Consistent with liso-cel studies in other histologies, 16 patients received either a DL1 of 50  106 (n
¼ 6) or a DL2 of 100  106 (n ¼ 10) CAR T cells [21].
In 75%, high-risk features were present: a TP53
mutation, a complex karyotype, or del17p; and 100%
and 50% had prior ibrutinib or venetoclax, respectively. The reported ORR in 15 patients at 6 months
with minimal residual disease (MRD) negative state
was 67%.
Pertaining to toxicities, only one patient developing grade 3 CRS and three patients grade 3 NAE
were reported thus far. TRANSCEND-CLL 004 is
currently accruing in a dose expansion phase in
patients with CLL/SLL with prior exposure to BTK
and BCL-2 inhibitors, with additional cohorts
investigating the role of treatment with a ibrutinib
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or venetoclax administered concurrently with lisocel.
At the American Society of Hematology meeting
in December 2020, results from 19 patients on the
TRANSCEND-CLL 004 who received ibrutinib with
liso-cel were reported [22]. With more than 1 month
follow-up, the ORR was 95% with 47% CR,
including 17 (89%) achieved undetectable MRD in
blood by ﬂow cytometry and 15 (79%) in BM by
next-generation sequencing. The combination was
safe with no DLT, only one patient with grade 3 or
higher CRS and three patients with grade 3 or
higher NAE were reported. Ibrutinib-related
adverse events were observed in 13 patients, with
more than half experiencing diarrhea, and only one
developing atrial ﬁbrillation.
4.3. Liso-cel beyond MCL and CLL
Other studies investigating liso-cell in various B
cell malignancies are actively accruing. The TRANSCENDWORLD trial (ClinicalTrials.gov Identiﬁer:
NCT03484702) is investigating liso-cel in a variety of
B-cell malignancies. It is a single-arm, multi-cohort,
multi-center, phase 2 study aimed at determining
the safety and efﬁcacy of liso-cel in adults with
aggressive B-cell NHL including double hit highgrade B cell lymphomas, primary CNS lymphoma,
and grade 3b FL. This study is accruing in Europe
and Japan. Also, TRANCEND FL (ClinicalTrials.gov
Identiﬁer: NCT04245839) is investigating liso-cel in
relapsed or refractory FL (Grade 1, 2, or 3a) and
marginal zone lymphoma (MZL) in those who had
received two to three lines of prior therapy. These
studies are anticipated to report results by the end
of 2021.

5. Discussion
CAR T cell therapy has revolutionized the treatment of R/R DLBCL and other B cell lymphoid
malignancies and has improved the therapeutic
outlook of these diseases. Liso-cel and other CD19
CAR T cell products are demonstrating encouraging
response rates in the setting of a very resistant disease. Although limited by the absence of randomized controlled trials (RCTs), published data appear
to show a lower incidence of CRS with liso-cel,
using the same grading Lee et al. [9] criteria, when
compared to axi-cel. A lower incidence and severity
of NAE with liso-cel versus axi-cel also appears to
be the case. Comparing the toxicity proﬁle of liso-cel
versus tisagenlecleucel is more challenging because
the JULIET study used a different set of grading
criteria to assess severity of CRS, known as the Penn
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grading system [12]. Notably, the Penn grading
system appears to result in higher rates of severe
CRS when compared to the Lee et al. [9] criteria
used in both TRANSCEND NHL 001 and ZUMA-1
[12].
To our knowledge, there are no RCTs that
compare these three products head-to-head and,
presently, choice of a particular product is based on
physician familiarity with the product and/or center
preference. In our opinion, important criteria to also
consider when selecting one product over another
are related to anticipated toxicity(ies) and timeliness
and manufacturing success.

6. Future direction
The results of ongoing trials exploring the efﬁcacy
and safety of liso-cel in other B cell histologies are
highly awaited. Given the high efﬁcacy and favorable toxicity proﬁle of liso-cel in large B cell lymphoma, it is expected that the results of these trials
will lend FDA approval for liso-cel in other B cell
histologies.
Currently liso-cel is approved for patients who
have received two or more prior lines of systemic
treatment. TRASCEND PILOT (NCT03483103) is
currently registered and investigates liso-cel in
aggressive B cell lymphoma after failure of only one
line of systemic therapy. JCAR017 is also being
investigated in the TRANSFORM (NCT03575351)
trial against the current standard of care (SOC) of
salvage chemoimmunotherapy followed by highdose chemotherapy and auto-HCT in patients with
R/R aggressive B cell lymphoma. Pending the results of these clinical trials, we may see a shift in the
current second-line SOC for patients with R/R
aggressive B cell lymphomas. This is of signiﬁcance
as with the current SOC of salvage chemoimmunotherapy followed by auto-HCT, long-term
remissions are seen in only about 50% of patients
[23].
The low rates of high-grade toxicity observed with
liso-cel in TRANSCEND-001 are encouraging for
continued expansion of outpatient administration of
CAR T cell products. TRANSCEND-OUTREACH007 (NCT03744676) is currently exploring the safety
and efﬁcacy of liso-cel in the outpatient setting. A
recent study reported efﬁcacy and safety data for 53
patients who received liso-cel as an outpatient [24].
Twenty-three patients were 65 years or older with 16
having tumor burden. CRS and NAEs of any grade
were reported in 34% and 26% patients, respectively
[24]. High-grade CRS or NAEs were reported in
only two patients and were reversible. The median
time to onset of CRS and NAE was 5 (2e9) and 8.5
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(3e22) days, respectively. Tocilizumab and/or corticosteroids for treatment of CRS and/or NAE was
required in 15% of patients. Thirty (57%) patients
required hospitalization at a median of 5.5 (range,
2e22) days after infusion. Only two were admitted
to the ICU. Efﬁcacy and safety data were consistent
with patients who received liso-cel in the inpatient
setting [24].
Recently, to improve on the current development
of CAR T cell therapy, including liso-cel, the Nex-T
platform was developed. Nex-T utilized machine
learning to optimize patient selection and process
improvements with the goal of increasing turnaround time, and reducing costs while maintaining
or improving on liso-cel efﬁcacy. The Nex-T CD19
CAR T or CC-97540 (NCT04231747) was recently
opened and is currently enrolling in a phase 1 dose
escalation study.

[8]

[9]

[10]

[11]

[12]
[13]

Authors’ contributions
All authors have contributed signiﬁcantly to this
review by writing, revising and approving the ﬁnal
version of the manuscript.

[14]

Declaration of Competing Interest

[15]

The authors declare that they have no known
competing ﬁnancial interests or personal relationships that could have appeared to inﬂuence the
work reported in this paper.

[16]

[17]

References
[1] Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M,
Bittencourt H, et al. tisagenlecleucel in children and young
adults with B-cell lymphoblastic leukemia. N Engl J Med
2018;378:439e48.
[2] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB,
Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell
therapy in refractory large B-cell Lymphoma. N Engl J Med
2017;377:2531e44.
[3] Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P,
McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;
380:45e56.
[4] Abramson JS, Palomba ML, Gordon LI, Lunning MA,
Wang M, Arnason J, et al. Lisocabtagene maraleucel for
patients with relapsed or refractory large B-cell lymphomas
(TRANSCEND NHL 001): a multicentre seamless design
study. Lancet 2020;396:839e52.
[5] Wang M, Munoz J, Goy A, Locke FL, Jacobson CA,
Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or
refractory mantle-cell lymphoma. N Engl J Med 2020;382:
1331e42.
[6] Crump M, Neelapu SS, Farooq U, Van Den Neste E,
Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse
large B-cell lymphoma: results from the international
SCHOLAR-1 study. Blood 2017;130:1800e8.
[7] Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der
Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in

[18]
[19]

[20]

[21]

[22]

[23]

relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540e5.
Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D,
Linch DC, Trneny M, et al. Rituximab maintenance therapy
after autologous stem-cell transplantation in patients with
relapsed CD20(þ) diffuse large B-cell lymphoma: ﬁnal
analysis of the collaborative trial in relapsed aggressive
lymphoma. J Clin Oncol 2012;30:4462e9.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N,
Jensen M, et al. Current concepts in the diagnosis and
management of cytokine release syndrome. Blood 2014;124:
188e95.
Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A,
et al. Matching-adjusted indirect treatment comparison of
liso-cel versus axi-cel in relapsed or refractory large B cell
lymphoma. J Hematol Oncol 2021;14:140.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ,
Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma
(ZUMA-1): a single-arm, multicentre, phase 1e2 trial. Lancet
Oncol 2019;20:31e42.
Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of
cytokine release syndrome associated with the CAR T cell
therapy tisagenlecleucel. J Hematol Oncol 2018;11:35.
Jacobson C, Chavez JC, Sehgal AR, William BM, Munoz J,
Salles G, et al. Primary analysis of Zuma-5: a phase 2 study of
axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/
refractory (R/R) indolent non-Hodgkin lymphoma (iNHL).
Blood 2020;136:40e1.
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A,
Flowers CR. 2016 US lymphoid malignancy statistics by
World Health Organization subtypes. CA Cancer J Clin 2016;
66:443e59.
Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma.
J Clin Oncol 2016;34:1256e69.
Cheah CY, Chihara D, Romaguera JE, Fowler NH,
Seymour JF, Hagemeister FB, et al. Patients with mantle cell
lymphoma failing ibrutinib are unlikely to respond to
salvage chemotherapy and have poor outcomes. Ann Oncol
2015;26:1175e9.
Palomba ML, Gordon LI, Siddiqi T, Abramson JS,
Kamdar M, Lunning MA, et al. Safety and preliminary efﬁcacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in Transcend
NHL 001. Blood 2020;136:10e1.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics,
2021. CA Cancer J Clin 2021;71:7e33.
Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J,
Kumar A. Reduced intensity is preferred over myeloablative
conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: a systematic review/meta-analysis.
Hematol Oncol Stem Cell Ther 2018;11:53e64.
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH,
et al. Feasibility and efﬁcacy of CD19-targeted CAR T cells
with concurrent ibrutinib for CLL after ibrutinib failure.
Blood 2020;135:1650e60.
Siddiqi T, Dorritie KA, Soumerai JD, Stephens DM,
Dubovsky JA, Gillenwater HH, et al. TRANSCEND CLL 004:
Minimal residual disease (MRD) negative responses after
lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19directed CAR T cell product, in patients (pts) with relapsed/
refractory chronic lymphocytic leukemia or small lymphocytic
lymphoma (CLL/SLL). J Clin Oncol 2019;37(15_suppl):7501.
Wierda WG, Dorritie KA, Munoz J, Stephens DM,
Solomon SR, Gillenwater HH, et al. Transcend CLL 004:
phase 1 cohort of lisocabtagene maraleucel (liso-cel) in
combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Blood 2020;136:39e40.
Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G,
Aljurf MD, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:168e175

cell transplantation. Biol Blood Marrow Transplant 2014;20:
1729e36.
[24] Bachier CR, Godwin JE, Andreadis C, Palomba ML,
Abramson JS, Sehgal AR, et al. Outpatient treatment with

175

lisocabtagene maraleucel (liso-cel) across a variety of clinical
sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). J Clin Oncol
2020;38:8037.

